Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

NeoGenomics Laboratories

Biotech & Life Sciences · Fort Myers, United States · Founded 2002 · IPO 2013 Unicorn

Cancer Reference laboratory

Valuation
$1.47B
Market cap · May/2026
Revenue
$727M
Latest reported FY
EBITDA
$56M
Latest reported FY

Global footprint

Where NeoGenomics Laboratories has talent and traffic

AI talent share
0.3% of workforce is AI talent
(6 of 1,757 staff)
Core AI30.17%
Other AI30.17%
Non-AI workforce1,75199.66%
Workforce by country
10 countries with
team presence
🇺🇸 United States95.2%
🇬🇧 United Kingdom2.9%
🇮🇳 India1.1%
🇨🇭 Switzerland0.2%
🇷🇺 Russia0.1%
Top 5 of 10 shown
Web traffic by country
57K monthly visits
across markets
🇺🇸 United States84%
🇮🇳 India5.6%
🇬🇧 United Kingdom5.4%
🇨🇦 Canada2.6%
🇵🇭 Philippines1.2%
Top 5 markets shown

Patent intelligence

$12M patent portfolio · 11 active families

Estimated portfolio value
$12M
0.83% of market cap · 26.3× smaller than top peer Exact Sciences ($319M)
11 active patent families
Where NeoGenomics Laboratories innovates OncologyBioinformaticsWild typeLocked nucleic acidPathology

Where NeoGenomics Laboratories concentrates vs peers

Each axis is a top-10 topic across NeoGenomics Laboratories and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

NeoGenomics Laboratories's 4 investments and acquisitions.

Every disclosed deal where NeoGenomics Laboratories appeared as a backer or acquirer, 2014–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across NeoGenomics Laboratories's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where NeoGenomics Laboratories deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        NeoGenomics Laboratories's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about NeoGenomics Laboratories

        An AI-synthesized read of the highest-engagement posts about NeoGenomics Laboratories on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See NeoGenomics Laboratories on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.